- Home
- DSP vs MGNX Comparison
DSP vs MGNX Comparison
Compare DSP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- MGNX
- Stock Information
- Founded
- DSP 1999
- MGNX 2000
- Country
- DSP United States
- MGNX United States
- Employees
- DSP N/A
- MGNX N/A
- Industry
- DSP EDP Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- MGNX Health Care
- Exchange
- DSP Nasdaq
- MGNX Nasdaq
- Market Cap
- DSP 291.3M
- MGNX 257.3M
- IPO Year
- DSP 2021
- MGNX 2013
- Fundamental
- Price
- DSP $19.17
- MGNX $3.00
- Analyst Decision
- DSP Strong Buy
- MGNX Hold
- Analyst Count
- DSP 7
- MGNX 10
- Target Price
- DSP $18.14
- MGNX $7.17
- AVG Volume (30 Days)
- DSP 201.6K
- MGNX 496.5K
- Earning Date
- DSP 03-03-2025
- MGNX 03-06-2025
- Dividend Yield
- DSP N/A
- MGNX N/A
- EPS Growth
- DSP N/A
- MGNX N/A
- EPS
- DSP 0.08
- MGNX N/A
- Revenue
- DSP $263,587,000.00
- MGNX $141,329,000.00
- Revenue This Year
- DSP $28.26
- MGNX $174.73
- Revenue Next Year
- DSP $12.19
- MGNX N/A
- P/E Ratio
- DSP $252.08
- MGNX N/A
- Revenue Growth
- DSP 23.73
- MGNX 16.68
- 52 Week Low
- DSP $7.19
- MGNX $2.95
- 52 Week High
- DSP $21.74
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- DSP 54.30
- MGNX 37.54
- Support Level
- DSP $16.78
- MGNX $3.00
- Resistance Level
- DSP $19.95
- MGNX $3.22
- Average True Range (ATR)
- DSP 0.90
- MGNX 0.17
- MACD
- DSP -0.12
- MGNX -0.02
- Stochastic Oscillator
- DSP 71.99
- MGNX 7.69
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).